Results for quarter and year ended 31-Mar-26
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals reported standalone revenue of Rs 10,498 crores for FY26, up 10.7% from Rs 9,485 crores in FY25. Profit after tax grew 16.1% to Rs 2,192 crores from Rs 1,888 crores. The company completed acquisition of controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) for approximately Rs 12,537 crores in January 2026, significantly increasing borrowings. Finance costs surged 60% to Rs 341 crores due to acquisition financing. The Board recommended a final dividend of Rs 9 per share, taking total dividend for FY26 to Rs 38 per share (including Rs 29 interim dividend). The company also sought shareholder approval for QIP issuance up to Rs 5,000 crores.
Strong bottom-line growth with PAT up 16.1% despite heavy acquisition-related costs and higher debt. The large JB Pharma acquisition significantly increased leverage but should expand revenue base going forward. Shareholders receive healthy dividend payouts.